Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma

Journal of Pathology

Volumn 213, Issue 4, 2007, Pages 429-440

  Tedoldi, S ^a   Mottok, A ^b   Ying, J ^c   Paterson, J C ^a   Cui, Y ^c   Facchetti, F ^d   Van Krieken, J H J M ^e   Ponzoni, M ^f   Ozkal S ^a   Masir, N ^a   Natkunam, Y ^g   Pileri, S A ^h   Hansmann, M L ^b   Mason, D Y ^a   Tao, Q ^c   Marafioti, T ^a,i  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF BRESCIA   (Italy)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Ctr of Cell and Molec Pharmacol   (Italy)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Immunohistochemistry; LPHL; Methylation; Microdissection

Indexed keywords

CD19 ANTIGEN; CD37 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PROTEIN BCL 6;

ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL LOSS; CONTROLLED STUDY; DNA EXTRACTION; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOID CELL; METHYLATION; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REED STERNBERG CELL;

B-LYMPHOCYTES; BIOLOGICAL MARKERS; BURKITT LYMPHOMA; DNA METHYLATION; DOWN-REGULATION; GERMINAL CENTER; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MICRODISSECTION; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED;

EID: 36749049316     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2242     Document Type: Article

References (56)

1. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997;337:453-458.
2. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994;91:10962-10966.
3. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505- 1512.
4. Mason DY, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peeters C, et al. Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity. Am J Surg Pathol 1994;18:526-530.
5. Masir N, Marafioti T, Jones M, Natkunam Y, Rudiger T, Hansmann ML, et al. Loss of CD19 expression in B-cell neoplasms. Histopathology 2006;48:239-246.
6. Marafioti T, Pozzobon M, Hansmann ML, Delsol G, Pileri SA, Mason DY. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004;103:188-193.
7. Ushmorov A, Leithauser F, Sakk O, Weinhausel A, Popov SW, Moller P, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006;107:2493-2500.
8. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
9. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO Classification: Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2001.
10. Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004;23:1326-1331.
11. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11:2091-2102.
12. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 1999;155:619-625.
13. Marafioti T, Jabri L, Pulford K, Brousset P, Mason DY, Delsol G. Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. Br J Haematol 2003;120:671-678.
14. Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J, et al. Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol 1981;101:111-124.
15. Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, Gerdes J, et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982;66:615-632.
16. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993;9:1-25.
17. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003;111:529-537.
18. Ushmorov A, Ritz O, Hummel M, Leithauser F, Moller P, Stein H, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004;104:3326-3334.
19. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, Collins G, et al. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica 2006;91:772-780.
20. Delsol G, Meggetto F, Brousset P, Cohen-Knafo E, al Saati T, Rochaix P, et al. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen. Am J Pathol 1993;142:1729-1738.
21. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nature Immunol 2006;7:207-215.
22. Renne C, Martin-Subero JI, Eickernjager M, Hansmann ML, Kuppers R, Siebert R, et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol 2006;169:655-664.
23. Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997;94:9337-9342.
24. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997;337:459-465.
25. Marafioti T, Jones M, Facchetti F, Diss TC, Du MQ, Isaacson PG, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003;102:2868-2876.
26. Tiacci E, Brune V, Eckerle S, Mechtersheimer G, Bräuninger A, Hansmann M-L, et al. Gene expression profiling of primary Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) and their relationship with primary mediastinal B-cell lymphoma (PMBCL). XIII Meeting of the European Association for Haematopathology. Vienna, Austria, 7-12 October 2006 Book of Abstracts, p. 151.
27. Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma. Blood 2006;108:1013- 1020.
28. Tedoldi S, Paterson JC, Hansmann ML, Natkunam Y, Rudiger T, Angelisova P, et al. Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood 2006;107:213-221.
29. Masir N, Jones M, Pozzobon M, Marafioti T, Volkova OY, Mechetina LV, et al. Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. Br J Haematol 2004;127:335-343.
30. Natkunam Y, Lossos IS, Taidi B, Zhao S, Lu X, Ding F, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-3986.
31. Tedoldi S, Paterson JC, Cordell J, Tan SY, Jones M, Manek S, et al. Jaw1/LRMP, a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. J Pathol 2006;209:454-463.
32. Marafioti T, Mancini C, Ascani S, Sabattini E, Zinzani PL, Pozzobon M, et al. Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica 2004;89:957-964.
33. Korkolopoulou P, Cordell J, Jones M, Kaklamanis L, Tsenga A, Gatter KC, et al. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease. Histopathology 1994;24:511-515.
34. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-1899.
35. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001;97:496-501.
36. Uherova P, Valdez R, Ross CW, Schnitzer B, Finn WG. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol 2003;119:192-198.
37. Watanabe K, Yamashita Y, Nakayama A, Hasegawa Y, Kojima H, Nagasawa T, et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000;36:353-361.
38. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002;20:1278-1287.
39. Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-777.
40. Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-1147.
41. Garcia-Cosio M, Santon A, Martin P, Camarasa N, Montalban C, Garcia JF, et al. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol 2004;17:1531-1538.
42. Norton AJ, Isaacson PG. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. Am J Pathol 1987;128:225-240.
43. Pozzobon M, Marafioti T, Hansmann ML, Natkunam Y, Mason DY. Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. Br J Haematol 2004;124:519-533.
44. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development, is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001;159:1807- 1814.
45. Loddenkemper C, Anagnostopoulos I, Hummel M, Johrens-Leder K, Foss HD, Jundt F, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004;202:60-69.
46. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92:1308-1316.
47. Buettner M, Greiner A, Avramidou A, Jack HM, Niedobitek G. Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hematol Oncol 2005;23:127-132.
48. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113.
49. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002;21:4908-4920.
50. Jundt F, Kley K, Anagnostopoulos I, Schulze Probsting K, Greiner A, Mathas S, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002;99:3060-3062.
51. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846-852.
52. Bai M, Panoulas V, Papoudou-Bai A, Horianopoulos N, Kitsoulis P, Stefanaki K, et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma 2006;47:495-501.
53. Falini B, Bigerna B, Pasqualucci L, Fizzotti M, Martelli MF, Pileri S, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996;87:465-471.
54. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol 1999;112:101-107.
55. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000;157:709-715.
56. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004;164:873- 881.